help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rao, R. H.
Right arrow Articles by Spathis, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, R. H.
Right arrow Articles by Spathis, G. S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMIODARONE HYDROCHLORIDE
*IODINE

Journal of Clinical Endocrinology & Metabolism, Vol 62, 563-568, Copyright © 1986 by Endocrine Society


ARTICLES

Iodine kinetic studies during amiodarone treatment

RH Rao, VR McCready and GS Spathis

Iodine kinetic studies were performed serially in 15 patients taking 300 mg amiodarone/day for 6 months to assess the biological significance of the high iodine content of the drug. Urinary inorganic iodide excretion increased from 0.25 +/- 0.03 (+/- SE) mumol/mmol creatinine before treatment to over 7 mumol/mmol during therapy. Thyroid iodide clearance fell from 5.93 +/- 0.82 ml/min to less than 0.5 ml/min, while plasma inorganic iodide rose from 0.05 +/- 0.01 mumol/liter to approximately 2.2 mumol/liter during treatment. Thyroid absolute iodide uptake rose from 16.3 +/- 2.7 to 54.6 +/- 5.7 nmol/h after 6 weeks of therapy (P less than 0.001). Thereafter, it progressively declined, but it was still significantly elevated (32.0 +/- 4.3 nmol/h) after 24 weeks (P less than 0.01). The calculated daily excretion of inorganic iodide rose to over 80 mumol during the study, accounting for about 10% of amiodarone iodine. During this time, the patients all had the characteristic plasma thyroid hormone changes associated with amiodarone therapy, i.e. increased T4, free T4, and rT3 and decreased T3, while remaining clinically euthyroid. The massive increase in available inorganic iodide during amiodarone treatment is probably responsible for the induction of both the hypothyroidism and the thyrotoxicosis that can occur in patients receiving the drug.


This article has been cited by other articles:


Home page
EndocrinologyHome page
S. Tedelind, F. Larsson, C. Johanson, H. C. van Beeren, W. M. Wiersinga, E. Nystrom, and M. Nilsson
Amiodarone Inhibits Thyroidal Iodide Transport in Vitro by a Cyclic Adenosine 5'-Monophosphate- and Iodine-Independent Mechanism
Endocrinology, June 1, 2006; 147(6): 2936 - 2943.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
K.-C. Loh
Current concepts in medicine: Amiodarone-induced thyroid disorders: a clinical review
Postgrad. Med. J., March 1, 2000; 76(893): 133 - 140.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
J. Wolff
Perchlorate and the Thyroid Gland
Pharmacol. Rev., March 1, 1998; 50(1): 89 - 106.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C M Newman, A Price, D W Davies, T A Gray, and A P Weetman
Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy
Heart, February 1, 1998; 79(2): 121 - 127.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society